EAS guidance regarding combining lipid-modifying therapy

Watch the video and learn on how to integrate recommendations by European Atherosclerosis Society (EAS) Task Force on combining lipid-modifying therapy into routine practice and have positive impact on atherosclerotic cardiovascular disease (ASCVD) trajectory and burden in high- and very-high-risk patients.

MAT-BH-2200016/v1/Jan 2022